These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 24980688)
1. Experimental appendicitis and appendectomy modulate the CCL20-CCR6 axis to limit inflammatory colitis pathology. Cheluvappa R Int J Colorectal Dis; 2014 Oct; 29(10):1181-8. PubMed ID: 24980688 [TBL] [Abstract][Full Text] [Related]
2. T helper type 17 pathway suppression by appendicitis and appendectomy protects against colitis. Cheluvappa R; Luo AS; Grimm MC Clin Exp Immunol; 2014 Feb; 175(2):316-22. PubMed ID: 24666024 [TBL] [Abstract][Full Text] [Related]
3. The Role of Specific Chemokines in the Amelioration of Colitis by Appendicitis and Appendectomy. Cheluvappa R; Thomas DG; Selvendran S Biomolecules; 2018 Jul; 8(3):. PubMed ID: 30037025 [TBL] [Abstract][Full Text] [Related]
4. Protective pathways against colitis mediated by appendicitis and appendectomy. Cheluvappa R; Luo AS; Palmer C; Grimm MC Clin Exp Immunol; 2011 Sep; 165(3):393-400. PubMed ID: 21707591 [TBL] [Abstract][Full Text] [Related]
5. Endothelin and vascular remodelling in colitis pathogenesis--appendicitis and appendectomy limit colitis by suppressing endothelin pathways. Cheluvappa R; Eri R; Luo AS; Grimm MC Int J Colorectal Dis; 2014 Nov; 29(11):1321-8. PubMed ID: 25085204 [TBL] [Abstract][Full Text] [Related]
6. Identification of New Potential Therapies for Colitis Amelioration Using an Appendicitis-Appendectomy Model. Cheluvappa R Inflamm Bowel Dis; 2019 Feb; 25(3):436-444. PubMed ID: 30329049 [TBL] [Abstract][Full Text] [Related]
7. Autophagy suppression by appendicitis and appendectomy protects against colitis. Cheluvappa R; Luo AS; Grimm MC Inflamm Bowel Dis; 2014 May; 20(5):847-55. PubMed ID: 24694792 [TBL] [Abstract][Full Text] [Related]
9. Expression of CCL20 and Its Corresponding Receptor CCR6 Is Enhanced in Active Inflammatory Bowel Disease, and TLR3 Mediates CCL20 Expression in Colonic Epithelial Cells. Skovdahl HK; Granlund Av; Østvik AE; Bruland T; Bakke I; Torp SH; Damås JK; Sandvik AK PLoS One; 2015; 10(11):e0141710. PubMed ID: 26536229 [TBL] [Abstract][Full Text] [Related]
10. Modulation of interferon activity-associated soluble molecules by appendicitis and appendectomy limits colitis-identification of novel anti-colitic targets. Cheluvappa R; Eri R; Luo AS; Grimm MC J Interferon Cytokine Res; 2015 Feb; 35(2):108-15. PubMed ID: 25243802 [TBL] [Abstract][Full Text] [Related]
11. C-C Motif Ligand 20 (CCL20) and C-C Motif Chemokine Receptor 6 (CCR6) in Human Peripheral Blood Mononuclear Cells: Dysregulated in Ulcerative Colitis and a Potential Role for CCL20 in IL-1β Release. Skovdahl HK; Damås JK; Granlund AVB; Østvik AE; Doseth B; Bruland T; Mollnes TE; Sandvik AK Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347808 [TBL] [Abstract][Full Text] [Related]
12. Production of CCL20 on nucleus pulposus cells recruits IL-17-producing cells to degenerated IVD tissues in rat models. Zhang Y; Liu L; Wang S; Zhao Y; Liu Y; Li J; Nie L; Cheng L J Mol Histol; 2016 Feb; 47(1):81-9. PubMed ID: 26704184 [TBL] [Abstract][Full Text] [Related]
13. CCR6(-) regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals. Loiseau C; Requena M; Mavigner M; Cazabat M; Carrere N; Suc B; Barange K; Alric L; Marchou B; Massip P; Izopet J; Delobel P Mucosal Immunol; 2016 Sep; 9(5):1137-50. PubMed ID: 26883727 [TBL] [Abstract][Full Text] [Related]
14. The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease. Dohlman TH; Chauhan SK; Kodati S; Hua J; Chen Y; Omoto M; Sadrai Z; Dana R Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4081-91. PubMed ID: 23702781 [TBL] [Abstract][Full Text] [Related]
15. CCR6/CCL20 chemokine axis in human immunodeficiency virus immunity and pathogenesis. Lee AYS; Körner H J Gen Virol; 2017 Mar; 98(3):338-344. PubMed ID: 28005525 [TBL] [Abstract][Full Text] [Related]
16. An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Comerford I; Bunting M; Fenix K; Haylock-Jacobs S; Litchfield W; Harata-Lee Y; Turvey M; Brazzatti J; Gregor C; Nguyen P; Kara E; McColl SR Bioessays; 2010 Dec; 32(12):1067-76. PubMed ID: 20954179 [TBL] [Abstract][Full Text] [Related]
17. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Meitei HT; Jadhav N; Lal G Autoimmun Rev; 2021 Jul; 20(7):102846. PubMed ID: 33971346 [TBL] [Abstract][Full Text] [Related]
18. CC chemokine receptor 6 (CCR6) in the pathogenesis of systemic lupus erythematosus. Lee AY; Körner H Immunol Cell Biol; 2020 Nov; 98(10):845-853. PubMed ID: 32634857 [TBL] [Abstract][Full Text] [Related]
19. SMAD4 Suppresses Colitis-associated Carcinoma Through Inhibition of CCL20/CCR6-mediated Inflammation. Hanna DN; Smith PM; Novitskiy SV; Washington MK; Zi J; Weaver CJ; Hamaamen JA; Lewis KB; Zhu J; Yang J; Liu Q; Beauchamp RD; Means AL Gastroenterology; 2022 Nov; 163(5):1334-1350.e14. PubMed ID: 35863523 [TBL] [Abstract][Full Text] [Related]
20. CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation. Kulkarni N; Meitei HT; Sonar SA; Sharma PK; Mujeeb VR; Srivastava S; Boppana R; Lal G J Autoimmun; 2018 Mar; 88():121-130. PubMed ID: 29126851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]